Leaders in transforming your health
Osteoarthritis and Depression
Chronic joint pain or osteoarthritis sometimes go hand-in-hand with depressed mood. But which comes first, the depression or the osteoarthritis? Understanding more about this answer could possibly change your life.
Symptoms of depression can include:
- Persistent sad, anxious or "empty" mood
- Feelings of hopelessness or pessimism
- Feelings of guilt, worthlessness or helplessness
- Loss of interest or pleasure in hobbies and activities that were once enjoyed, including sex
- Decreased energy or fatigue
- Difficulty concentrating, remembering or making decisions
- Insomnia, early-morning awakening or oversleeping
- Appetite and/or weight changes
- Thoughts of death or suicide or even suicide attempts
- Restlessness or irritability
Depression and anxiety among US adults: associations with body mass index.
Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH.
1Division of Adult and Community Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Background:Obesity is associated with an increased risk of developing a variety of chronic diseases, most of which are associated with psychiatric disorders. We examined the associations of depression and anxiety with body mass index (BMI) after taking into consideration the obesity-related comorbidities (ORCs) and other psychosocial or lifestyle factors.Methods:We analyzed the data collected from 177 047 participants (aged>/=18 years) in the 2006 Behavioral Risk Factor Surveillance System. Current depression was assessed by the Patient Health Questionnaire-8 diagnostic algorithm. Lifetime diagnoses of depression, anxiety and ORCs were self-reported. The prevalence of the three psychiatric disorders was age standardized to the 2000 US population. Multivariate-adjusted prevalence ratios were computed to test associations of depression and anxiety with BMI using SUDAAN software.Results:The age-adjusted prevalence of current depression, lifetime diagnosed depression and anxiety varied significantly by gender. Within each gender, the prevalence of the three psychiatric disorders was significantly higher in both men and women who were underweight (BMI<18.5 kg/m(2)), in women who were overweight (BMI: 25-<30 kg/m(2)) or obese (BMI>/=30 kg/m(2)), and in men who had class III obesity (BMI>/=40 kg/m(2)) than in those with a normal BMI (18.5-<25 kg/m(2)). After adjusting for demographics, ORCs, lifestyle or psychosocial factors, compared with men with a normal BMI, men with a BMI>/=40 kg/m(2) were significantly more likely to have current depression or lifetime diagnosed depression and anxiety; men with a BMI<18.5 kg/m(2) were also significantly more likely to have lifetime diagnosed depression. Women who were either overweight or obese were significantly more likely than women with a normal BMI to have all the three psychiatric disorders.Conclusions:Our results demonstrate that disparities in the prevalence of depression and anxiety exist among people with different BMI levels independent of their disease status or other psychosocial or lifestyle factors.International Journal of Obesity advance online publication, 6 January 2009; doi:10.1038/ijo.2008.268.
According to the doctors conducting this study, “These are the first data to demonstrate that psychosocial factors predict the risk for developing the metabolic syndrome by multiple definitions. Psychosocial factors may play a causal role in the chain of events leading to the metabolic syndrome.”
[Räikkönen, K, Matthews, KA, Kuller, LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care. 2007;30(10):2761.]
In the article above from the American Journal of Medicine, doctors wrote about the importance of pharmacologic and non-pharmacologic interventions for depression in people with joint pain. We would like to explore evidence for one form of non-drug intervention here, because this type of data lies, in part, behind our enthusiasm for a self-care program that supports healthy joints. As we've noted previously, the Insulite System for Healthy Joints incorporates elements of diet, nutrition, and lifestyle that have been shown in previous studies to have an influence on both depression and on osteoarthritis. One intervention with a fair amount of evidence is a nutrient molecule called SAMe.
The United States Department of Health and Human Services has a department called the Agency for Health Care Research and Quality (AHCRQ). They undertook an investigation that examined the benefits of SAMe (S-adenosyl-methionine) on depression and on osteoarthritis (SAMe Treats Osteoarthritis, Depression, and Liver Disease, Agency for Healthcare Research and Quality. 2002;64:1–3). SAMe is a compound made in the body from the dietary amino acid methionine. It is crucial to processes in the brain called methylation reactions, which help make our neurotransmitters. It is also important in joint function. In all, SAMe influences some 100 metabolic reactions in the human body.
The Agency for Health Care Research Quality identified 47 studies involving SAMe for depression and 14 studies for SAMe for osteoarthritis.
Twenty eight of these studies were included in an analysis of the benefits of SAMe to decrease symptoms of depression.
- SAMe vs. Placebo. Compared to placebo, treatment with SAMe was associated with an improvement of approximately 6 points in the score of the Hamilton Rating Scale for Depression measured at 3 weeks. This degree of improvement is statistically as well as clinically significant and is equivalent to a partial response to treatment. According to the researchers, “The results generally favored SAMe compared to placebo.”
- SAMe vs. Antidepressant Drugs. Use of SAMe resulted in outcomes similar to that achieved by antidepressant drugs.
Ten studies were included in an analysis of the benefits of SAMe to decrease pain of osteoarthritis.
- SAMe vs. Placebo. One large randomized clinical trial showed an effect size in favor of SAMe of 0.20 compared to placebo, thus demonstrating a decrease in the pain of osteoarthritis.
- SAMe vs. Anti-inflammatory Drugs. Use of SAMe resulted in outcomes similar to that achieved by anti-inflammatory drugs (such as ibuprofen, indomethacin, aspirin, and others).
Depression may also be linked to development of another factor that is often linked to osteoarthritis—the metabolic syndrome. Recall that the term metabolic syndrome is often used to describe disturbances in blood glucose, blood insulin, and blood fats that falls short of true diabetes.




















